Literature DB >> 6374032

Nucleoproteins of animal influenza viruses, in contrast to those of human strains, are not cleaved in infected cells.

O Zhirnov, A G Bukrinskaya.   

Abstract

We previously reported that nucleoproteins (NPs) of human influenza viruses are cleaved in infected cells and, as a result, two forms of NP, uncleaved (mol. wt. 56000) and cleaved (mol. wt. 53000) were accumulated late in infection. Here, we report that NPs of animal influenza viruses of non-human origin (isolated from pigs, equids , seals, whales, birds) exhibited proteolytic resistance in infected cells and did not undergo a change in mol. wt. in the course of infection. The resistance of the animal virus NPs to proteolytic cleavage was shown to be a virus-specific property and not the consequence of a low level of proteolysis in infected cells. Influenza A/H3N2 viruses isolated from swine in Hong Kong in 1976 were found to have a cleavable NP like that of 'human' viruses, supporting the hypothesis concerning the 'human' origin of these strains. The NP of human influenza virus (A/Aichi/2/68) adapted to an animal host (mouse) retained susceptibility to limited intracellular proteolysis. Thus, NP resistance to cleavage seems to be a stable viral characteristic enabling the NP56 ---- NP53 modification to be used as an indication of the origin of influenza viruses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6374032     DOI: 10.1099/0022-1317-65-6-1127

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity.

Authors:  T Watanabe; S Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Sequence of the nucleoprotein (NP) gene of the influenza Alanas acuta/Primorje/695/76 (H2N3) virus.

Authors:  J Mandler; M S Kunerl; S Ludwig; M E Herget; C Scholtissek
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

3.  The host origin of influenza A viruses can be assessed by the intracellular cleavage of the viral nucleocapsid protein. Brief report.

Authors:  O P Zhirnov
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

4.  Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Authors:  Arwen F Altenburg; Carolien E van de Sandt; Stella E van Trierum; Heidi L M De Gruyter; Peter R W A van Run; Ron A M Fouchier; Kenny Roose; Xavier Saelens; Asisa Volz; Gerd Sutter; Rory D de Vries; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

5.  The N-terminal extension of the influenza B virus nucleoprotein is not required for nuclear accumulation or the expression and replication of a model RNA.

Authors:  M P Stevens; W S Barclay
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Caspase-dependent N-terminal cleavage of influenza virus nucleocapsid protein in infected cells.

Authors:  O P Zhirnov; T E Konakova; W Garten; H Klenk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Influenza virus pathogenicity is determined by caspase cleavage motifs located in the viral proteins.

Authors:  Oleg P Zhirnov; Vladimir V Syrtzev
Journal:  J Mol Genet Med       Date:  2009-01-03

Review 8.  Caspase cleavage of viral proteins, another way for viruses to make the best of apoptosis.

Authors:  A Richard; D Tulasne
Journal:  Cell Death Dis       Date:  2012-03-08       Impact factor: 8.469

9.  Alphavirus replication in cultured cells and infected animals is inhibited by antiproteinase agents.

Authors:  O P Zhirnov; A V Ovcharenko; E E Melnikova; A G Bukrinskaya
Journal:  Antiviral Res       Date:  1986-08       Impact factor: 5.970

10.  Human Mig chemokine: biochemical and functional characterization.

Authors:  F Liao; R L Rabin; J R Yannelli; L G Koniaris; P Vanguri; J M Farber
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.